Results 101 to 110 of about 16,334 (217)

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Insulin Signalling‐Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Insulin substantially promotes the growth of malignant cells that overexpress the insulin receptor (INSR), and insulin excess has been recognised as a cancer‐promoting factor in patients. Interferon‐induced transmembrane protein 1 (IFITM1) is also overexpressed in various cancers.
Ji‐Young Lim, Yeojin Kim, Sung‐Soo Park, Jungyeon Lee, Chang‐Ki Min   +4 more
wiley   +1 more source

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course

Nephrology, Volume 31, Issue 6, June 2026.
ABSTRACT Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a form of monoclonal gammopathy of renal significance (MGRS) in which monoclonal immunoglobulin deposits are found within the glomerulus, without involvement of other renal compartments.
Hayley J. Duxbury, David A. Brown, Adrian Y. S. Lee, Germaine Wong, Fiona Kwok, Seethalakshmi Viswanathan   +5 more
wiley   +1 more source

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance. [PDF]

J Adv Pract Oncol
Noonan K, Brigle K, Gleason C, Bellerive C, Steinbach M, Doss D.   +5 more
europepmc   +1 more source

High-throughput monoclonal gammopathy community monitoring programme. [PDF]

Br J Haematol
Agarwal G, Campbell L, Carty O, Larham J, Knight E, Moore S, Gooding S, Kothari J, Browning J, Evans J, Ferguson L, Vieira A, Swanborough L, Roberts P, Bateman E, Sadler R, Ramasamy K.   +16 more
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Hematuria and Proteinuria in a Patient with Monoclonal Gammopathy of Renal Significance. [PDF]

Kidney360
Zhang M, Fu Y, Chen XJ.
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report. [PDF]

BMC Nephrol
Li XY, Chen QN, Fang JN, Zeng ZC, Pan Y.
europepmc   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source